ArticleNature communications2022
Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 71 citations in OpenAlex.
- Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.Frontiers in immunology · 2022Trial
- Mucosal antibody and cytokine responses to SARS-CoV-2 variants of concerns.BMC infectious diseases · 2026Article
- Symptom progression and viral shedding dynamics in children and adolescents with asymptomatic and mild COVID-19 infections.BMC infectious diseases · 2026Article
- Article
- Real-world immune dynamics following COVID-19 vaccination and breakthrough infection: a paired-sample study in Zhejiang Province, China.Frontiers in immunology · 2026Article
- Reading of human acute immune dynamics in omicron SARS-CoV-2 breakthrough infection.Emerging microbes & infections · 2025Article
- Cytokine and Antibody Isotype Responses in Vaccinated Healthcare Workers with SARS-CoV-2 Breakthrough Infections.Viruses · 2025Article
- Impact of Population Immunity and Public Health Measures on the Transmission of Omicron Subvariants BA.2 and BA.5 in Hong Kong.The Journal of infectious diseases · 2025Article
- Epidemiological features and risk factors of SARS-CoV-2 reinfection: a retrospective cohort analysis in Xiamen, China.Journal of thoracic disease · 2025Article
- Variants and vaccines impact nasal immunity over three waves of SARS-CoV-2.Nature immunology · 2025Article
- Heterologous prime-pull mucosal vaccination with an adjuvanted RBD vaccine elicits robust IgA production and protects against SARS-CoV-2.Frontiers in immunology · 2025Article
- SLAMF7 defines subsets of human effector CD8 T cells.Scientific reports · 2024Article
- Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections.NPJ vaccines · 2024Article
- Article
- SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire.Cell reports. Medicine · 2024Article
- Article
- Observational
- Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants.Immunity · 2024Article
- Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants.medRxiv : the preprint server for health sciences · 2024Article
- M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SARS-CoV-2 Omicron variant has more than 15 mutations in the receptor binding domain of the Spike protein enabling increased transmissibility and viral escape from antibodies in vaccinated individuals. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a super-spreader event have robust recall response of humoral and pre-existing cellular immunity induced by the vaccines, and an emergent de novo T cell response to non-Spike antigens. Individuals with Omicron SARS-CoV-2 breakthrough infections have significantly increased activated SARS-CoV-2 wild type Spike-specific cytotoxic T cells, activated follicular helper (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.